Statin therapy: A potentially useful peri-operative intervention in patients with cardiovascular disease

Anaesthesia

Volumn 60, Issue 11, 2005, Pages 1106-1114

  Biccard, Bruce M ^a,b   Sear, J W ^a   Foex P ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATINE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ANTILIPEMIC AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE HEART INFARCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROTIC PLAQUE; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SURGERY; HEMODYNAMICS; HUMAN; LONG TERM CARE; MENTAL DISEASE; MUSCLE DISEASE; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PLEIOTROPY; RESPIRATORY TRACT DISEASE; REVIEW; RHABDOMYOLYSIS; TREATMENT OUTCOME; DRUG ADMINISTRATION; METHODOLOGY;

ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PERIOPERATIVE CARE; TREATMENT OUTCOME;

EID: 27744560162     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2044.2005.04405.x     Document Type: Review

References (54)

1. NCEPOD. Then and Now: The 2000 Report of the National Confidential Enquiry into Perioperative Deaths: London: The National Confidential Enquiry into Postoperative Deaths, 2001.
2. NCEPOD. Extremes of Age: The 1999 Report of the National Confidential Enquiry into Perioperative Deaths. London: The National Confidential Enquiry into Postoperative Deaths, 1999.
3. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. New England Journal of Medicine 2004; 351: 2795-804.
4. Godet G, Riou B, Bertrand M, et al. Does preoperative coronary angioplasty improve perioperative cardiac outcome? Anesthesiology 2005; 102: 739-46.
5. Stevens RD, Burri H, Tramër MR. Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review. Anesthesia and Analgesia 2003; 97: 623-33.
6. Devereaux PJ, Yusuf S, Yang H, Choi PT-L, Guyatt GH. Are the recommendations to use perioperative β-blocker therapy in patients undergoing noncardiac surgery based on reliable evidence? Canadian Medical Association Journal 2004; 171: 245-7.
7. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative β-blockers in non-cardiac surgery? Systematic review and meta-analysis of randomized controlled trials. British Medical Journal 2005; 331: 313-21.
8. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
9. Mason JC. Statins and their role in vascular protection. Clinical Science (London) 2003; 105: 251-66.
10. Libby P. Inflammation in atherosclerosis. Nature 2000; 420: 868-74.
11. Laws PE, Spark JI, Cowled PA, Fitridge RA. The role of statins in vascular disease. European Journal of Vascular and Endovascular Surgery 2004; 27: 6-16.
12. Albert MA, Danielson E, Rifai PM, et al. for the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. Journal of the American Medical Association 2001; 286: 64-70.
13. Laufs U, Wassmann S, Hilgers S, Ribaudo N, Bohm M, Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. American Journal of Cardiology 2001; 88: 1306-7.
14. Dawood MM, Gupta DK, Southern J, Walia A, Atkinson JB, Eagle KA. Pathology of fatal myocardial infarction: implications regarding pathophysiology and prevention. International Journal of Cardiology 1996; 57: 37-44.
15. Badner NH, Knill RL, Brown JE, Novik TV, Gelb AW. Myocardial infarction after noncardiac surgery. Anesthesiology 1998; 88: 572-8.
16. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine 1995; 333: 1301-7.
17. Sacks FM, Pfeffer MA, Moye LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. New England Journal of Medicine 1996; 335: 1001-9.
18. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine 1998; 339: 1349-57.
19. Downs JR, Clearfield M, Weis S, et al. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Journal of the American Medical Association 1998; 279: 1615-22.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
21. Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atrovastatin and Coronary heart disease Evaluation (GREACE) Study. Current Medical Research and Opinion 2002; 18: 220-8.
22. Prosper Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
23. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). Journal of the American Medical Association 2002; 288: 2998-3007.
24. Sever PS, Dahlof B, Poulter NR, et al. for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients with average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003; 361: 1149-58.
25. Schiele R, Gitt AK, Heer T, et al. Early statin use in myocardial infarction is associated with a reduced hospital mortality. Results of MITRA-2. Circulation 2000; 102: II-435, (Abstract) 2117.
26. Arntz H-R, Agrawal R, Wunderlich W, et al. Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event (The randomised lipid-coronary artery disease [L-CAD] study). American Journal of Cardiology 2000; 86: 1293-8.
27. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. Journal of the American Medical Association 2001; 285: 430-6.
28. Bybee KA, Wright RS, Williams BA, Murphy JG, Holmes DR, Kopecky SL. Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. American Journal of Cardiology 2001; 87: 771-4.
29. Schwartz GG, Olsson AG, Ezekowitz MD, et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. Journal of the American Medical Association 2001; 285: 1711-8.
30. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063-8.
31. Giugliano RP, Antman EM, Thompson SL, McCabe CH, Braunwald E. Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower post-discharge 1-year mortality. Journal of the American College of Cardiology 2001; 37: 316A, (Abstract) 1053-91.
32. Heeschen C, Hamm CW, Laufs U, et al. for the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
33. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003; 107: e27.
34. Liem AH, van Boven AJ, Veeger NJGM, et al. for the Fluvastatin On Risk Diminishment after Acute myocardial infarction (FLORIDA) Study Group. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized controlled trial. European Heart Journal 2002; 23: 1931-7.
35. Newby LK, Kristinsson A, Bhapkar MV, et al. for the SYMPHONY and 2nd SYMPHONY Investigators. Early statin initiation and outcomes in patients with acute coronary syndromes. Journal of the American Medical Association 2002; 287: 3087-95.
36. Spencer FA, Allegrone J, Goldberg RJ, et al. for the GRACE investigators. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Annals of Internal Medicine 2004; 140: 857-66.
37. Cannon CP, Braunwald E, McCabe CH, et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. New England Journal of Medicine 2004; 350: 1495-504.
38. De Lemos JA, Blazing MA, Wiviott SD, et al. for the A to Z investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial. Journal of the American Medical Association 2004; 292: 1307-16.
39. Saab FA, Eagle KA, Kline-Rogers E, et al. for the Michigan Cardiovascular Outcomes Research and Reporting Program of the University of Michigan Cardiovascular Center. Comparisons of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. American Journal of Cardiology 2004; 94: 1166-8.
40. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac surgery. Circulation 2003; 107: 1848-51.
41. Landesberg G, Mosseri M, Wolf YG, et al. Preoperative thallium scanning, selective coronary revascularization, and long-term survival after major vascular surgery. Circulation 2003; 108: 177-83.
42. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. American Journal of Medicine 2004; 116: 96-103.
43. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. Journal of Vascular Surgery 2004; 39: 967-75.
44. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. European Journal of Vascular and Endovascular Surgery 2004; 28: 343-52.
45. Lindenauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. Journal of the American Medical Association 2004; 291: 2092-9.
46. O'Neil-Callahan K, Katsimaglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery. The Statins for Risk Reduction in Surgery (StaRRS) Study. Journal of the American College of Cardiology 2005; 45: 336-42.
47. Schouten O, Kertai MD, Bax JJ, et al. Safety of perioperative statin use in high-risk patients undergoing major vascular surgery. American Journal of Cardiology 2005; 95: 658-60.
48. Dotani MI, Elnicki M, Jain AC, Gibson CM. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. American Journal of Cardiology 2000; 86: 1128-30.
49. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004; 110 (Suppl. II:): 45-9.
50. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 1999; 100: 1043-9.
51. Spencer FA, Fonarow GC, Frederick PD, et al. for the National Registry of Myocardial Infarction Investigators. Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction. Archives of Internal Medicine 2004; 164: 2162-8:
52. Grundy SM, Cleeman JI, Merz CNB, et al. for Coordinating Committee of the National Cholesterol Education Program. Implications of the recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 2004; 110: 227-39.
53. Newby DE, Nimmo AF. Prevention of cardiac complications of non-cardiac surgery: stenosis and thrombosis. British Journal of Anaesthesia 2004; 92: 628-32.
54. Biccard BM, Sear JW, Foëx P. The pharmacoeconomics of perioperative statin therapy. Anaesthesia 2005; 60.